JP7788787B2 - 遺伝子発現増強のための組成物および方法 - Google Patents

遺伝子発現増強のための組成物および方法

Info

Publication number
JP7788787B2
JP7788787B2 JP2019529995A JP2019529995A JP7788787B2 JP 7788787 B2 JP7788787 B2 JP 7788787B2 JP 2019529995 A JP2019529995 A JP 2019529995A JP 2019529995 A JP2019529995 A JP 2019529995A JP 7788787 B2 JP7788787 B2 JP 7788787B2
Authority
JP
Japan
Prior art keywords
nucleic acid
virus
dlp
sequence
rna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019529995A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020500536A5 (OSRAM
JP2020500536A (ja
Inventor
カート アイバー カムルド，
マウン ニャン ウィン，
ナサニエル スティーブン ワン，
ジェイソン デハート，
Original Assignee
ヤンセン ファーマシューティカルズ，インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヤンセン ファーマシューティカルズ，インコーポレーテッド filed Critical ヤンセン ファーマシューティカルズ，インコーポレーテッド
Publication of JP2020500536A publication Critical patent/JP2020500536A/ja
Publication of JP2020500536A5 publication Critical patent/JP2020500536A5/ja
Priority to JP2023115763A priority Critical patent/JP2023156294A/ja
Application granted granted Critical
Publication of JP7788787B2 publication Critical patent/JP7788787B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/00041—Use of virus, viral particle or viral elements as a vector
    • C12N2770/00042—Use of virus, viral particle or viral elements as a vector virus or viral particle as vehicle, e.g. encapsulating small organic molecule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36061—Methods of inactivation or attenuation
    • C12N2770/36062—Methods of inactivation or attenuation by genetic engineering
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/30—Vector systems having a special element relevant for transcription being an enhancer not forming part of the promoter region
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/10—Vectors comprising a special translation-regulating system regulates levels of translation
    • C12N2840/105—Vectors comprising a special translation-regulating system regulates levels of translation enhancing translation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2019529995A 2016-12-05 2017-12-04 遺伝子発現増強のための組成物および方法 Active JP7788787B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023115763A JP2023156294A (ja) 2016-12-05 2023-07-14 遺伝子発現増強のための組成物および方法

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201662430250P 2016-12-05 2016-12-05
US62/430,250 2016-12-05
US201762486361P 2017-04-17 2017-04-17
US62/486,361 2017-04-17
US201762587954P 2017-11-17 2017-11-17
US62/587,954 2017-11-17
PCT/US2017/064561 WO2018106615A2 (en) 2016-12-05 2017-12-04 Compositions and methods for enhancing gene expression

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023115763A Division JP2023156294A (ja) 2016-12-05 2023-07-14 遺伝子発現増強のための組成物および方法

Publications (3)

Publication Number Publication Date
JP2020500536A JP2020500536A (ja) 2020-01-16
JP2020500536A5 JP2020500536A5 (OSRAM) 2020-12-10
JP7788787B2 true JP7788787B2 (ja) 2025-12-19

Family

ID=61157280

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019529995A Active JP7788787B2 (ja) 2016-12-05 2017-12-04 遺伝子発現増強のための組成物および方法
JP2023115763A Pending JP2023156294A (ja) 2016-12-05 2023-07-14 遺伝子発現増強のための組成物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023115763A Pending JP2023156294A (ja) 2016-12-05 2023-07-14 遺伝子発現増強のための組成物および方法

Country Status (10)

Country Link
US (2) US11845939B2 (OSRAM)
EP (1) EP3548625B1 (OSRAM)
JP (2) JP7788787B2 (OSRAM)
KR (1) KR102655641B1 (OSRAM)
CN (1) CN110352247B (OSRAM)
AU (1) AU2017372731B2 (OSRAM)
BR (1) BR112019011661A2 (OSRAM)
CA (1) CA3045650A1 (OSRAM)
MX (1) MX2019006467A (OSRAM)
WO (1) WO2018106615A2 (OSRAM)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3443107A1 (en) 2016-04-13 2019-02-20 Synthetic Genomics, Inc. Recombinant arterivirus replicon systems and uses thereof
WO2018075235A1 (en) 2016-10-17 2018-04-26 Synthetic Genomics, Inc. Recombinant virus replicon systems and uses thereof
EP3548625B1 (en) 2016-12-05 2024-06-26 Janssen Pharmaceuticals, Inc. Compositions and methods for enhancing gene expression
EA202091517A1 (ru) 2017-12-19 2020-11-03 Янссен Сайенсиз Айрлэнд Анлимитед Компани Способы и устройство для доставки вакцин против вируса гепатита b (hbv)
US11020476B2 (en) 2017-12-19 2021-06-01 Janssen Sciences Ireland Unlimited Company Methods and compositions for inducing an immune response against Hepatitis B Virus (HBV)
US11021692B2 (en) 2017-12-19 2021-06-01 Janssen Sciences Ireland Unlimited Company Hepatitis B virus (HBV) vaccines and uses thereof
BR112020014525A2 (pt) 2018-01-19 2020-12-08 Janssen Pharmaceuticals, Inc. Induzir e intensificar respostas imunes utilizando sistemas de replicon recombinantes
AU2019222560B2 (en) 2018-02-17 2025-07-03 Flagship Pioneering Innovations V, Inc. Compositions and methods for membrane protein delivery
MX2021004032A (es) 2018-10-08 2021-07-06 Janssen Pharmaceuticals Inc Replicones basados en alfavirus para la administracion de bioterapeuticos.
CN113631718A (zh) 2018-11-14 2021-11-09 旗舰先锋创新V股份有限公司 用于特定隔室货物递送的组合物和方法
TWI852977B (zh) 2019-01-10 2024-08-21 美商健生生物科技公司 前列腺新抗原及其用途
WO2020181058A1 (en) * 2019-03-05 2020-09-10 Massachusetts Institute Of Technology Dna launched rna replicon system (drep) and uses thereof
GB201908729D0 (en) * 2019-06-18 2019-07-31 Imp College Innovations Ltd RNA construct
US20220313815A1 (en) * 2019-06-20 2022-10-06 Janssen Sciences Ireland Unlimited Company Self-replicating rna molecules for hepatitis b virus (hbv) vaccines and uses thereof
CN214973877U (zh) 2019-08-09 2021-12-03 胡桃钳医疗公司 用于形成治疗性多核苷酸的微流体设备及微流体路径装置
CA3161800A1 (en) 2019-11-18 2021-05-27 Janssen Biotech, Inc. Vaccines based on mutant calr and jak2 and their uses
AU2020417800A1 (en) 2019-12-31 2022-07-14 Elixirgen Therapeutics, Inc. Temperature-based transient delivery of nucleic acids and proteins to cells and tissues
TW202144388A (zh) 2020-02-14 2021-12-01 美商健生生物科技公司 在卵巢癌中表現之新抗原及其用途
TW202144389A (zh) 2020-02-14 2021-12-01 美商健生生物科技公司 在多發性骨髓瘤中表現之新抗原及其用途
US11744887B2 (en) 2020-03-09 2023-09-05 Arcturus Therapeutics, Inc. Coronavirus vaccine compositions and methods
EP4135757A1 (en) 2020-04-13 2023-02-22 Janssen Biotech, Inc. Psma and steap1 vaccines and their uses
CA3183500A1 (en) 2020-05-11 2021-11-18 Janssen Pharmaceuticals, Inc. Sars-cov-2 vaccines
BR112022022942A2 (pt) 2020-05-11 2022-12-13 Janssen Pharmaceuticals Inc Réplicon de rna que codifica uma proteína spike de coronavírus estabilizada
EP4175721A1 (en) 2020-07-06 2023-05-10 Janssen Biotech, Inc. Prostate neoantigens and their uses
WO2022009052A2 (en) 2020-07-06 2022-01-13 Janssen Biotech, Inc. Prostate neoantigens and their uses
EP4178613A1 (en) 2020-07-08 2023-05-17 Janssen Sciences Ireland Unlimited Company Rna replicon vaccines against hbv
AU2021325945A1 (en) 2020-08-14 2023-04-06 Arcturus Therapeutics, Inc. Method of lyophilizing lipid nanoparticles
CN112029781B (zh) * 2020-08-14 2023-01-03 中山大学 一种新型冠状病毒SARS-CoV-2的安全型复制子系统及其应用
GB202020063D0 (en) * 2020-12-17 2021-02-03 Imperial College Innovations Ltd RNA construct
GB202020061D0 (en) * 2020-12-17 2021-02-03 Imp College Innovations Ltd RNA construct
WO2022133230A1 (en) 2020-12-18 2022-06-23 Janssen Pharmaceuticals, Inc. Combination therapy for treating hepatitis b virus infection
WO2022232687A1 (en) * 2021-04-30 2022-11-03 Greenlight Biosciences, Inc. Messenger rna therapeutics and compositions
TW202313967A (zh) * 2021-07-30 2023-04-01 美商亞克圖羅斯醫療公司 Ｒｎａ疫苗
GEAP202516650A (en) 2022-05-12 2025-03-10 Msd Int Business Gmbh Stabilized pre-fusion hmpv fusion proteins
EP4587048A1 (en) 2022-09-14 2025-07-23 Ceva Santé Animale Treatment of atopic dermatitis using self-replicating rna expressing il-31
WO2024139837A1 (en) * 2022-12-27 2024-07-04 Yu Chien Hung Recombinant nucleic acids, kits comprising the same, and uses thereof in treating coronavirus infection
WO2024259214A1 (en) 2023-06-14 2024-12-19 Ceva Sante Animale Self-amplifying rna expressing one or more infectious laryngotracheitis virus ( ilt) antigens
WO2025110984A1 (en) * 2023-11-21 2025-05-30 Hydrogene Therapeutics, Inc. Compositions and methods for treating wilson's disease

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004055161A2 (en) 2002-12-12 2004-07-01 The Board Of Regents Of The University Of Texas System Large scale production of packaged alphavirus replicons
US20080279891A1 (en) 2004-07-09 2008-11-13 Johnston Robert E Viral Adjuvants
US20140079734A1 (en) 2012-09-20 2014-03-20 Uab Research Foundation Methods and Compositions for Alphavirus Replicons

Family Cites Families (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU561343B2 (en) 1981-10-19 1987-05-07 Genentech Inc. Human immune interferon by recombinant dna
US4738927A (en) 1982-03-31 1988-04-19 Ajinomoto Co. Inc. Gene coded for interleukin-2 polypeptide, recombinant DNA carrying the said gene, a living cell line possessing the recombinant DNA, and method for producing interleukin-2 using the said cell
US4966843A (en) 1982-11-01 1990-10-30 Cetus Corporation Expression of interferon genes in Chinese hamster ovary cells
US4892743A (en) 1983-12-21 1990-01-09 Schering Corporation Novel hybrid interferon species
EP0165942A1 (en) 1983-12-23 1986-01-02 Monash University PRODUCTION OF HUMAN INTERFERON-$g(a)
AU594014B2 (en) 1984-03-21 1990-03-01 Research Corporation Technologies, Inc. Recombinant DNA molecules
US4810643A (en) 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
JPS63500636A (ja) 1985-08-23 1988-03-10 麒麟麦酒株式会社 多分化能性顆粒球コロニー刺激因子をコードするｄｎａ
US5017691A (en) 1986-07-03 1991-05-21 Schering Corporation Mammalian interleukin-4
US5116742A (en) 1986-12-03 1992-05-26 University Patents, Inc. RNA ribozyme restriction endoribonucleases and methods
EP0446283A4 (en) 1988-12-01 1992-01-08 Univ North Carolina Synthetic interleukin-6
US5225337A (en) 1989-09-25 1993-07-06 Innovir Laboratories, Inc. Ribozyme compositions and methods for use
US5246921A (en) 1990-06-26 1993-09-21 The Wistar Institute Of Anatomy And Biology Method for treating leukemias
US5780036A (en) 1991-08-26 1998-07-14 The Scripps Research Institute Peptides for inducing cytotoxic T lymphocyte responses to hepattis B virus
AU702367B2 (en) 1993-08-02 1999-02-18 Scripps Research Institute, The Peptides for inducing cytotoxic T lymphocyte responses to hepatitis B virus
SE9401709D0 (sv) * 1994-05-18 1994-05-18 Mathilda Sjoeberg Improved alphavirus vectors for expression of heterologous DNA
US5792462A (en) 1995-05-23 1998-08-11 University Of North Carolina At Chapel Hill Alphavirus RNA replicon systems
US6041252A (en) 1995-06-07 2000-03-21 Ichor Medical Systems Inc. Drug delivery system and method
DE19712889A1 (de) 1997-03-27 1998-10-01 Bosch Gmbh Robert Verfahren und Vorrichtung zur Ermittlung einer den Systemdruck in einem Bremskreis beschreibenden Größe
US6261281B1 (en) 1997-04-03 2001-07-17 Electrofect As Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells
CA2285056C (en) 1997-04-03 2004-12-14 Iacob Mathiesen Method for introducing pharmaceutical drugs and nucleic acids into skeletal muscle
US5873849A (en) 1997-04-24 1999-02-23 Ichor Medical Systems, Inc. Electrodes and electrode arrays for generating electroporation inducing electrical fields
GB0023203D0 (en) 2000-09-21 2000-11-01 Isis Innovation Vaccination method
US6117660A (en) 1997-06-10 2000-09-12 Cytopulse Sciences, Inc. Method and apparatus for treating materials with electrical fields having varying orientations
JP2002507985A (ja) 1997-06-30 2002-03-12 ローヌ−プーラン・ロレ・エス・アー 横紋筋に核酸を導入する改良法およびその組合せ
US5958060A (en) 1998-01-02 1999-09-28 General Electric Company Method and apparatus for clock control and synchronization
US20020164585A1 (en) * 1998-01-16 2002-11-07 Sean Chapman Method for enhancing RNA or protein production using non-native 5' untranslated sequences in recombinant viral nucleic acids
US6697669B2 (en) 1998-07-13 2004-02-24 Genetronics, Inc. Skin and muscle-targeted gene therapy by pulsed electrical field
US6319901B1 (en) 1998-10-15 2001-11-20 Ichor Medical Systems, Inc. Methods for prolonging cell membrane permeability
IL147343A0 (en) * 1999-07-21 2002-08-14 Large Scale Biology Corp Method for enhancing ran or protein production using non-native 5' untranslated sequences in recombinant viral nucleic acids
US20040213805A1 (en) 1999-10-12 2004-10-28 Verheije Monique Helene Deletions in arterivirus replicons
WO2002020721A2 (en) * 2000-09-07 2002-03-14 University Of North Carolina At Chapel Hill Vectors derived from south african arbovirus no. 86
US6538922B1 (en) 2000-09-27 2003-03-25 Sandisk Corporation Writable tracking cells
EP1195438A1 (en) * 2000-10-06 2002-04-10 Rijksuniversiteit te Groningen Genetic immunisation against cervical carcinoma
AU3163902A (en) 2000-11-23 2002-06-03 Bavarian Nordic Res Inst As Modified vaccinia ankara virus variant
AU2002242016A1 (en) 2001-02-01 2002-08-12 The Johns Hopkins University Nucleic acid derived vaccine that encodes an antigen linked to a polypeptide that promotes antigen presentation
EP1397498A1 (en) 2001-05-21 2004-03-17 ID-Lelystad, Instituut voor Dierhouderij en Diergezondheid B.V. Delections in arterivirus replicons
ATE354260T1 (de) 2001-07-19 2007-03-15 Ericsson Telefon Ab L M Verfahren und vorrichtung für die lösung der nummernübertragbarkeit am ursprungsort
US7204997B2 (en) 2002-01-29 2007-04-17 Supratek Pharma Inc. Responsive microgel and methods related thereto
US7245963B2 (en) 2002-03-07 2007-07-17 Advisys, Inc. Electrode assembly for constant-current electroporation and use
US8209006B2 (en) 2002-03-07 2012-06-26 Vgx Pharmaceuticals, Inc. Constant current electroporation device and methods of use
US6912417B1 (en) 2002-04-05 2005-06-28 Ichor Medical Systmes, Inc. Method and apparatus for delivery of therapeutic agents
US7328064B2 (en) 2002-07-04 2008-02-05 Inovio As Electroporation device and injection apparatus
EP1593738A4 (en) * 2003-01-30 2006-05-31 Shanghai Tengen Biomedical Co VIRUSELY PARTICULATE VACCINE WITH RECOMBINANT DENGUEVIRUS REPLICANT AS ITS SUPPORT
EP1651666B1 (en) 2003-07-11 2009-05-27 Alphavax, Inc. Alphavirus-based cytomegalovirus vaccines
US8080255B2 (en) 2003-07-11 2011-12-20 Novavax Inc. Functional influenza virus like particles (VLPs)
WO2005026316A2 (en) * 2003-09-15 2005-03-24 Bioption Ab Alphavirus vaccines
US20050070700A1 (en) 2003-09-30 2005-03-31 Matthias Giese Equine arteritis virus vaccine
US20050171044A1 (en) * 2003-12-24 2005-08-04 Stein David A. Oligonucleotide compound and method for treating nidovirus infections
NZ550342A (en) 2004-03-08 2010-06-25 Ichor Medical Systems Inc Improved apparatus for electrically mediated delivery of therapeutic agents
EP1751289B1 (en) 2004-05-18 2009-01-14 Alphavax, Inc. Tc-83-derived alphavirus vectors, particles and methods
KR100872840B1 (ko) * 2004-07-09 2008-12-22 (주)씨아이디 돼지생식기호흡기증후군 바이러스에 대한 전체-길이의감염성이 있는 cDNA 클론 및 이의 용도
JP2009511636A (ja) 2005-10-18 2009-03-19 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド アルファウイルスレプリコン粒子による粘膜免疫および全身免疫
EP1792996A1 (en) * 2005-12-01 2007-06-06 Consejo Superior de Investigaciones Cientificas Nucleic acid sequences encoding vaccines against Porcine reproductive and respiratory syndrome virus (PRRSV)
US8859198B2 (en) 2006-06-06 2014-10-14 Abl Sa Detection and use of antiviral resistance mutations
EP2062246A4 (en) 2006-08-18 2010-09-29 Univ North Carolina VACCINES AGAINST CHIMARICAL VIRUSES
US9452285B2 (en) 2006-10-17 2016-09-27 Vgx Pharmaceuticals, Inc. Electroporation devices and methods of using same for electroporation of cells in mammals
US20090018031A1 (en) 2006-12-07 2009-01-15 Switchgear Genomics Transcriptional regulatory elements of biological pathways tools, and methods
KR100836745B1 (ko) 2007-01-31 2008-06-10 (주)두비엘 Ｈｂｖ 백신 및 그의 제조 방법
PL2183368T3 (pl) 2007-06-21 2016-12-30 Kasety bez promotora do ekspresji alfawirusowych białek strukturalnych
WO2009056535A2 (en) 2007-10-29 2009-05-07 Genimmune N.V. Methods and kits for inducing a ctl response using a prime boost regimen
WO2011005799A2 (en) 2009-07-06 2011-01-13 Novartis Ag Self replicating rna molecules and uses thereof
SG178254A1 (en) 2009-08-07 2012-03-29 Transgene Sa Composition for treating hbv infection
WO2011082388A2 (en) * 2009-12-31 2011-07-07 Medigen, Inc . Infectious dna vaccines against chikungunya virus
PL3243526T3 (pl) 2010-07-06 2020-05-18 Glaxosmithkline Biologicals S.A. Dostarczanie rna w celu wyzwolenia wielu szlaków immunologicznych
EP2655621B1 (en) 2010-12-20 2018-05-23 The General Hospital Corporation Polycomb-associated non-coding rnas
ES2806263T3 (es) 2011-02-11 2021-02-17 Univ Pennsylvania Molécula de ácido nucleico que codifica la proteína del núcleo del virus de la hepatitis b y vacuna que comprende la misma
CN103687644B (zh) 2011-06-28 2016-11-09 艾诺奥医药品有限公司 微创性皮肤电穿孔装置
TWI575070B (zh) 2011-07-12 2017-03-21 傳斯堅公司 Ｈｂｖ聚合酶突變體
WO2013120499A1 (en) * 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly (a) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen
EP3348645B1 (en) * 2012-02-15 2020-06-03 CureVac AG Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen
EP2932993B1 (en) 2012-12-13 2017-03-29 Panasonic Healthcare Holdings Co., Ltd. Medicament injection device
WO2014170493A2 (en) 2013-04-19 2014-10-23 Novartis Ag Alphavirus vector
AU2014310935B2 (en) 2013-08-21 2019-11-21 CureVac SE Combination vaccine
US20170151339A1 (en) 2014-06-30 2017-06-01 Tarveda Therapeutics, Inc. Targeted conjugates and particles and formulations thereof
WO2016020538A1 (en) 2014-08-08 2016-02-11 Transgene Sa Hbv vaccine and antibody combination therapy to treat hbv infections
CA2962799A1 (en) 2014-10-01 2016-04-07 The Trustees Of The University Of Pennsylvania Vaccines having an antigen and interleukin-21 as an adjuvant
PT3280729T (pt) * 2015-04-08 2022-08-01 Novartis Ag Terapias para cd20, terapias para cd22 e terapias de combinação com uma célula que expressa o recetor de antigénio quimérico (car) para cd19
ES2875589T3 (es) 2015-05-15 2021-11-10 Curevac Ag Regímenes de sensibilización-refuerzo que implican la administración de al menos un constructo de ARNm
AU2016302237B2 (en) 2015-08-03 2022-08-04 The United States Of America, As Represented By The Secretary Department Of Health And Human Services Brachyury deletion mutants, non-yeast vectors encoding brachyury deletion mutants, and their use
SG11201808236YA (en) 2016-03-28 2018-10-30 Ichor Medical Systems Inc Method and apparatus for delivery of therapeutic agents
US11324819B2 (en) 2016-04-06 2022-05-10 University Of Washington Therapeutic vaccine for Hepatitis b virus (HBV) using the HBV core antigen
EP3443107A1 (en) 2016-04-13 2019-02-20 Synthetic Genomics, Inc. Recombinant arterivirus replicon systems and uses thereof
WO2018075235A1 (en) 2016-10-17 2018-04-26 Synthetic Genomics, Inc. Recombinant virus replicon systems and uses thereof
EP3548625B1 (en) 2016-12-05 2024-06-26 Janssen Pharmaceuticals, Inc. Compositions and methods for enhancing gene expression
JP6613399B2 (ja) 2017-06-05 2019-12-04 株式会社ビークル Ｈｂｖに対する免疫応答を生じさせるために用いられるウイルス様粒子
CN111542340B (zh) 2017-11-16 2023-12-19 华盛顿大学 治疗性乙型肝炎病毒(hbv)疫苗
US11021692B2 (en) 2017-12-19 2021-06-01 Janssen Sciences Ireland Unlimited Company Hepatitis B virus (HBV) vaccines and uses thereof
CN111836641A (zh) 2017-12-19 2020-10-27 杨森科学爱尔兰无限公司 乙型肝炎病毒(hbv)疫苗及其用途

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004055161A2 (en) 2002-12-12 2004-07-01 The Board Of Regents Of The University Of Texas System Large scale production of packaged alphavirus replicons
US20080279891A1 (en) 2004-07-09 2008-11-13 Johnston Robert E Viral Adjuvants
US20140079734A1 (en) 2012-09-20 2014-03-20 Uab Research Foundation Methods and Compositions for Alphavirus Replicons

Also Published As

Publication number Publication date
AU2017372731B2 (en) 2024-05-23
US20240209379A1 (en) 2024-06-27
WO2018106615A2 (en) 2018-06-14
EP3548625A2 (en) 2019-10-09
CA3045650A1 (en) 2018-06-14
EP3548625C0 (en) 2024-06-26
AU2017372731A1 (en) 2019-06-20
KR102655641B1 (ko) 2024-04-05
US11845939B2 (en) 2023-12-19
KR20190134590A (ko) 2019-12-04
MX2019006467A (es) 2019-12-09
CN110352247B (zh) 2024-06-28
JP2023156294A (ja) 2023-10-24
CN110352247A (zh) 2019-10-18
US20180171340A1 (en) 2018-06-21
BR112019011661A2 (pt) 2020-01-07
EP3548625B1 (en) 2024-06-26
WO2018106615A3 (en) 2018-08-09
JP2020500536A (ja) 2020-01-16

Similar Documents

Publication Publication Date Title
JP7788787B2 (ja) 遺伝子発現増強のための組成物および方法
JP7382230B2 (ja) 組み換えウイルスレプリコン系及びその使用
CN115927467B (zh) 用于多功能和有效的基因表达的rna复制子
JP2021511318A (ja) 組換えレプリコン系を使用する免疫応答の誘導および増強
KR20210074314A (ko) 생체치료제의 투여를 위한 알파바이러스 기반 레플리콘
US10435712B2 (en) Evolution of high-titer virus-like vesicles for vaccine applications
JP7769644B2 (ja) 多用途かつ効率的な遺伝子発現のためのｒｎａレプリコン
JP2024539089A (ja) 修飾複製可能ｒｎａの機能および関連する組成物を増加させるための変異を決定する方法ならびにそれらの使用
KR20160107195A (ko) Vlp-레플리콘을 이용한 클래스 ii mhc 항원의 전달에 의한 암 면역요법
EP4396359A1 (en) Modified alphaviruses with heterologous nonstructural proteins
CA3040264C (en) Recombinant virus replicon systems and uses thereof
JP2025505950A (ja) 機能性自己複製ｒｎａ分子を作製する方法
BR112018068381B1 (pt) Replicon de rna, sistema, dna, métodos in vitro para produção de uma proteína de interesse, célula inoculada procariótica, uso do replicon de rna e uso de um construto de rna

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20191127

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201029

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201029

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210831

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210914

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211209

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220214

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220628

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220927

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221128

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221228

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230314

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230714

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230818

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230818

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20231013

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251209

R150 Certificate of patent or registration of utility model

Ref document number: 7788787

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150